Arvinas Files 2024 Annual Report

Ticker: ARVN · Form: 10-K · Filed: Feb 11, 2025 · CIK: 1655759

Arvinas, Inc. 10-K Filing Summary
FieldDetail
CompanyArvinas, Inc. (ARVN)
Form Type10-K
Filed DateFeb 11, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $198.9 m, $367.3 million, $282.5 million
Sentimentneutral

Sentiment: neutral

Topics: annual-report, biopharmaceutical, sec-filing

TL;DR

ARVN filed its 2024 10-K, all systems go on reporting. Check financials.

AI Summary

Arvinas, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company is a biopharmaceutical company focused on developing orally bioavailable protein degrader medicines. It is registered in Delaware and headquartered in New Haven, Connecticut, with its common stock traded on The Nasdaq Global Select Market under the symbol ARVN. The filing indicates Arvinas has met all reporting requirements for the past 12 months and 90 days.

Why It Matters

This 10-K filing provides a comprehensive overview of Arvinas's financial health, operational performance, and strategic direction for the past fiscal year, crucial for investors assessing the company's value and future prospects.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Arvinas faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.

Key Players & Entities

  • Arvinas, Inc. (company) — Registrant
  • December 31, 2024 (date) — Fiscal year end
  • Delaware (jurisdiction) — State of incorporation
  • New Haven, Connecticut (location) — Principal executive offices
  • ARVN (ticker) — Trading symbol
  • The Nasdaq Global Select Market LLC (company) — Exchange

FAQ

What is Arvinas, Inc.'s primary business focus?

Arvinas, Inc. is a biopharmaceutical company focused on developing orally bioavailable protein degrader medicines.

In which state was Arvinas, Inc. incorporated?

Arvinas, Inc. was incorporated in Delaware.

What is the trading symbol for Arvinas, Inc.'s common stock?

The trading symbol for Arvinas, Inc.'s common stock is ARVN.

On which exchange is Arvinas, Inc. common stock traded?

Arvinas, Inc. common stock is traded on The Nasdaq Global Select Market LLC.

Has Arvinas, Inc. met its filing requirements for the past 12 months?

Yes, the filing indicates that Arvinas, Inc. has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.

Filing Stats: 4,376 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2025-02-11 17:16:45

Key Financial Figures

  • $0.001 — ch registered) Common stock, par value $0.001 per share ARVN The Nasdaq Global Selec
  • $198.9 m — n profitability. Our net losses totaled $198.9 million, $367.3 million and $282.5 millio
  • $367.3 million — Our net losses totaled $198.9 million, $367.3 million and $282.5 million for the years ended
  • $282.5 million — aled $198.9 million, $367.3 million and $282.5 million for the years ended December 31, 2024,

Filing Documents

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 78 Item 1B. Unresolved Staff Comments 127 Item 1C Cybersecurity 127 Item 2.

Properties

Properties 128 Item 3.

Legal Proceedings

Legal Proceedings 129 Item 4. Mine Safety Disclosures 129 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 130 Item 6. [Reserved] 131 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 131 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 149 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 149 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 149 Item 9A.

Controls and Procedures

Controls and Procedures 149 Item 9B. Other Information 152 Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspection 152 PART III Item 10. Directors, Executive Officers and Corporate Governance 153 Item 11.

Executive Compensation

Executive Compensation 153 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 153 Item 13. Certain Relationships and Related Transactions, and Director Independence 153 Item 14. Principal Accountant Fees and Services 153 PART IV Item 15. Exhibits, Financial Statement Schedules 154 Item 16. Form 10-K Summary 159 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

Forward-Looking Statements

Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "goals," "will," "would," "could," "should," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: the initiation, timing, progress and results of our current and future clinical trials of vepdegestrant, ARV-393 and ARV-102, and current clinical trials of bavdegalutamide, including statements regarding the period during which the results of the clinical trials will become available or the forum in which we will present such results; the timing of, and our ability to obtain, marketing approval of our product candidates, including vepdegestrant, and the ability of our product candidates, including vepdegestrant, to meet existing or future regulatory standards; the potential achievement of milestones and receipt of payments under our collaborations, including our collaboration with Pfizer Inc. entered into in July 2021; potential receipt of payments based on the achievement of milestones related to luxdegalutamide (ARV-766) and future royalties under our license agreement with Novartis Pharma AG; our plans to pursue research and development of other product candidates; our expectation to wind down our bavdegalutamide program after completion of current ongoing cl

Business

Item 1. Business. Overview, Programs and Pipeline We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, Discovery Engine, our technology platform to engineer proteolysis-targeting chimeras, or PROTAC protein degraders, we are pioneering the development of protein degradation therapies designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. We have a robust preclinical pipeline of PROTAC protein degraders targeting a broad range of intracellular disease targets, including those representing proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as "undruggable" targets. We are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in areas of unmet need, including oncology (including hematology and immuno-oncology), neuroscience, and other therapeutic areas. We and our collaborators have initiated programs across multiple therapeutic areas with the goal of developing and delivering life-changing therapies to patients in need. We are currently progressing multiple product candidates through clinical development programs, including vepdegestrant, targeting the estrogen receptor, or ER, for the treatment of locally advanced or metastatic ER positive / human epidermal growth factor receptor 2, or HER2, negative, or ER+/HER2-, breast cancer; ARV-393, targeting the B-cell lymphoma 6, or BCL6, protein for the treatment of relapsed/refractory non-Hodgkin Lymphoma, or NHL; and ARV-102, targeting the leucine-r

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.